Recent successes in development of orphan drugs to treat rare diseases are in stark contrast to the challenge of decreased productivity faced by the global pharmaceutical industry with traditional research and development (R&D) models for more common diseases. Following this trend, several large multinational pharmaceutical companies such as Pfizer and GlaxoSmithKline have established in-house business units specializing in rare diseases (1, 2) . Many others have been actively working to acquire or partner with orphan drug companies, e.g., Sanofi acquired the leading orphan drug company Genzyme in 2011 (2); Biogen has partnered with Ionis to target spinal muscular atrophy (SMA) and with Applied Genetics to develop gene therapies for X-linked retinoschisis (XLRS) (3) . Furthermore, several large companies specializing in rare diseases such as Shire and Alexion have seen tremendous growth over the past few years (2) . Rare diseases are now such an attractive sector that orphan drugs have become the global drug industry's leading area of specialization (Table 1) .
Despite recent success in the orphan drug sector, effective therapies are only available for less than 5% of over 7,000 rare diseases, many of which are lifethreatening and debilitating. The situation is even grimmer in China and many developing nations, where the vast majority of patients with a rare disease currently have no access to appropriate care due to low awareness of the diseases and limited access to specialists, diagnostic testing, and treatment. As a result, less than one-third of the > 500 orphan drugs that have been approved in the United States of America (USA) and other Western countries are available in China and developing nations. In China, the main type of indication for currently available orphan therapies is rare cancer, accounting for almost half of all orphan drugs (4) . Since the majority of orphan drugs in China are not covered by health insurance, this further limits accessibility because of the high cost of most orphan drugs, low reimbursement rates, and low incomes; this translates into less affordability for the majority of the Chinese rare disease patients (Table 2 ) (5). In addition, only a few drug companies in China are specializing in rare diseases mainly due to the lack of legislative incentives that have been deemed essential for the success of the orphan drug industry in the USA.
Since the Chinese Government launched its first pilot project in 2013 to improve healthcare for rare disease patients (6), significant progress has been made at every front in the fight against rare diseases in China (Supplemental Table S1 ) (6) (7) (8) (9) (10) . The recent announcement of the first National Committee of Experts on Rare Disease Treatment and Patient Protection (7) is another encouraging sign that policy-makers and legislators have begun to recognize the impact of rare diseases and are starting to consider those diseases as a national healthcare priority.
There are currently only a handful of drug companies in China with in-house R&D programs devoted to rare diseases, although this number is expected to grow tremendously thanks partly to increased public awareness. Chipscreen is a successful example, since the China Food and Drug Administration (CFDA) recently approved Chipscreen's innovative cancer drug Chidamide for the treatment of peripheral T-cell lymphoma (PTCL) Revolutionary technological advances in nextgeneration gene sequencing have enhanced our understanding of genetic risk factors and underlying genetic defects that are linked to rare diseases. Gene therapy has quickly emerged as an effective and powerful approach to treat or even potentially cure many rare diseases (Table 5) .
In order to maximize and efficiently utilize available resources to successfully develop orphan drugs to treat rare diseases in China, a framework is presented here with several specific recommendations for drug companies interested in capitalizing on opportunities in the market: 1) Drug companies need to work closely with all stakeholders, including policy makers and regulatory agencies as well as rare disease communities, to create a healthy ecosystem as is essential for life science innovation.
2) Chinese drug companies interested in rare diseases should adopt a global outlook by eyeing the global market while operating in China and they should foster innovation through global collaboration by tapping into the intelligence and expertise of Western companies and joining forces with global partners.
3) Drug companies should decide areas to focus on by adopting a systematic approach with pre-defined criteria based on in-depth analyses prior to embarking on a program targeting a specific rare disease. The final decision should represent the best opportunities based on the information and resources available and focus on urgent, unmet needs that are medically addressable and commercially viable in China and the rest of the world. Several key criteria include: i).Vast unmet needs with no or limited options available, and especially those with the greatest impact on China (20). Examples of major rare diseases in China include thalassemia, osteogenesis imperfecta, SMA, and Duchenne's muscular dystrophy (DMD) (20). (11) . Several newly established innovative biotech companies have been actively working in the area of rare diseases (Table 3 ), e.g., Hua Medicine has been working on several rare diseases such as fragile X syndrome (FXS) and Parkinson's disease -L-dopa-induced dyskinesia (PD-LID) (12) . Another new biotech company, Beijing Prosit Sole Biotechnology, has also devoted considerable resources to rare diseases including several rare immunological disorders (13) . In addition, Shanghai Genomics has recently launched a drug for the treatment of idiopathic pulmonary fibrosis (IPF) (14) .
A point worth noting is that many academic institutions and major hospitals in China have been playing an important role in translational medicine for the treatment of rare diseases, and particularly in the area of cutting-edge technologies. As an example, the Shanghai Institute of Materia Medica (SIMM) of the Chinese Academy of Sciences recently announced that one of their orphan drug programs targeting pulmonary arterial hypertension (PAH) was approved by the CFDA to begin human clinical trials (15) . With respect to cutting-edge technologies, Sichuan University's West China Hospital in Chengdu recently announced that they are preparing to conduct the world's first human trial using CRISPR gene editing technology (16) . In addition, a team of scientists from Tongji Medical College have, in collaboration with FivePlus Molecular Medicine Institute in Beijing, successfully conducted a long-term trial of gene therapy in human patients with a rare genetic disorder known as Leber's hereditary optic neuropathy (LHON) (17, 18) , more than 10 years after the world's first gene therapy was approved in China (19) .
Nonetheless, the orphan drug industry in China is still in its infancy with tremendous challenges to overcome. Compared to the USA and many Western countries with more mature industries as well as legislative and regulatory systems, currently, there are almost no large domestic pharmaceutical companies with significant resources allocated to rare diseases, although government funds allocated to rare disease research and DNA sequencing have increased significantly in China, along with funding from the private sector.
A major difference between the USA and China is that rare disease research and drug development are primarily driven by rare disease organizations and the private sector in the USA. Rare disease organizations played a critical role in the early stage of rare disease ii).Diseases with a more clearly defined history and progressive symptoms that respond to interventions with a clinically meaningful impact within a reasonable period. Additional features include biomarkers that can be used to predict disease progression, stratification of otherwise heterogeneous patient populations, and prediction of the patient response to treatment. Also critical are companion diagnostic kits based on reliable biomarkers that are available or easily developed.
iii). Easy access to local key opinion leaders (KOLs)/ hospitals in order to quickly identify and recruit patients for intervention trials and KOLs/hospitals who are willing to fiercely advocate on behalf of rare disease patients and drug companies.
iv). A rare indication with the same therapeutic target as a common disease is ideal, since it offers the potential for expanded indications in the future. This allows a company to build a portfolio based on multiple shots on goal with reduced risk and operational synergy.
4) Adopting a patient-centric approach, companies should create a corporate culture and business model by incorporating patients' perspective into program planning and execution. In fact, many rare disease patients and patient organizations have shown a strong desire and willingness to play a larger role in orphan drug development.
5) Drug companies should take advantage of favorable policies while establishing orphan drug R&D capacities in China. Historically, China has placed a high priority on biomedical research with strong governmental support and a favorable regulatory environment for cutting-edge technologies, such as gene and cell therapies (16, 19, (21) (22) (23) 24) . These technologies hold great promise for treating and even curing genetic diseases. The precision medicine initiative recently undertaken by the Chinese Government will no doubt further accelerate rare disease research in China.
6) Orphan drug development represents one of the best opportunities to create differentiated products to meeting vast unmet medical needs. Drug companies should embrace the recent CFDA reform favoring innovative development of drugs for a variety of medical needs, including rare diseases.
In conclusion, patients' needs should be the focus of coordinated national task forces and investigational networks on rare diseases, and these organizations need to be supported by a long-term strategy and sustained commitment from the Chinese Government. The recently released 13th National Five-Year Plan puts greater emphasis on healthcare and the pharmaceutical industry. The Plan specifically cites genetic research and precision medicine which will support and promote research and drug development for rare diseases. A systematic approach backed by national initiatives will pave the way for robust growth of the healthcare industry, including orphan drug development. With increasing government funding and support for innovative drug development, coupled with on-going regulatory reform, 'Made in China' orphan drugs may soon become a reality.
